Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $252.20 billion. The enterprise value is $275.74 billion.
| Market Cap | 252.20B |
| Enterprise Value | 275.74B |
Important Dates
The next confirmed earnings date is Tuesday, February 4, 2025, before market open.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Dec 16, 2024 |
Share Statistics
Merck & Co. has 2.53 billion shares outstanding. The number of shares has decreased by -0.25% in one year.
| Current Share Class | 2.53B |
| Shares Outstanding | 2.53B |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | -0.12% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 78.65% |
| Float | 2.53B |
Valuation Ratios
The trailing PE ratio is 20.86 and the forward PE ratio is 11.07. Merck & Co.'s PEG ratio is 0.27.
| PE Ratio | 20.86 |
| Forward PE | 11.07 |
| PS Ratio | 4.00 |
| Forward PS | 3.69 |
| PB Ratio | 5.67 |
| P/TBV Ratio | 43.52 |
| P/FCF Ratio | 16.99 |
| P/OCF Ratio | 13.81 |
| PEG Ratio | 0.27 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.03, with an EV/FCF ratio of 18.58.
| EV / Earnings | 22.70 |
| EV / Sales | 4.36 |
| EV / EBITDA | 12.03 |
| EV / EBIT | 14.59 |
| EV / FCF | 18.58 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.86.
| Current Ratio | 1.36 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 1.64 |
| Debt / FCF | 2.57 |
| Interest Coverage | 15.08 |
Financial Efficiency
Return on equity (ROE) is 28.33% and return on invested capital (ROIC) is 14.87%.
| Return on Equity (ROE) | 28.33% |
| Return on Assets (ROA) | 10.53% |
| Return on Capital (ROIC) | 14.87% |
| Revenue Per Employee | $877,417 |
| Profits Per Employee | $168,722 |
| Employee Count | 72,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.39 |
Taxes
In the past 12 months, Merck & Co. has paid $1.56 billion in taxes.
| Income Tax | 1.56B |
| Effective Tax Rate | 11.35% |
Stock Price Statistics
The stock price has decreased by -7.37% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -7.37% |
| 50-Day Moving Average | 101.51 |
| 200-Day Moving Average | 117.45 |
| Relative Strength Index (RSI) | 46.37 |
| Average Volume (20 Days) | 11,949,058 |
Short Selling Information
The latest short interest is 32.79 million, so 1.30% of the outstanding shares have been sold short.
| Short Interest | 32.79M |
| Short Previous Month | 26.23M |
| Short % of Shares Out | 1.30% |
| Short % of Float | 1.30% |
| Short Ratio (days to cover) | 2.70 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $63.17 billion and earned $12.15 billion in profits. Earnings per share was $4.78.
| Revenue | 63.17B |
| Gross Profit | 48.39B |
| Operating Income | 18.89B |
| Pretax Income | 15.23B |
| Net Income | 12.15B |
| EBITDA | 22.93B |
| EBIT | 18.89B |
| Earnings Per Share (EPS) | $4.78 |
Balance Sheet
The company has $14.59 billion in cash and $38.13 billion in debt, giving a net cash position of -$23.54 billion or -$9.30 per share.
| Cash & Cash Equivalents | 14.59B |
| Total Debt | 38.13B |
| Net Cash | -23.54B |
| Net Cash Per Share | -$9.30 |
| Equity (Book Value) | 44.56B |
| Book Value Per Share | 17.58 |
| Working Capital | 10.78B |
Cash Flow
In the last 12 months, operating cash flow was $18.26 billion and capital expenditures -$3.42 billion, giving a free cash flow of $14.84 billion.
| Operating Cash Flow | 18.26B |
| Capital Expenditures | -3.42B |
| Free Cash Flow | 14.84B |
| FCF Per Share | $5.87 |
Margins
Gross margin is 76.59%, with operating and profit margins of 29.91% and 19.23%.
| Gross Margin | 76.59% |
| Operating Margin | 29.91% |
| Pretax Margin | 21.72% |
| Profit Margin | 19.23% |
| EBITDA Margin | 36.29% |
| EBIT Margin | 29.91% |
| FCF Margin | 23.49% |
Dividends & Yields
This stock pays an annual dividend of $3.24, which amounts to a dividend yield of 3.25%.
| Dividend Per Share | $3.24 |
| Dividend Yield | 3.25% |
| Dividend Growth (YoY) | 5.41% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 67.79% |
| Buyback Yield | 0.25% |
| Shareholder Yield | 3.50% |
| Earnings Yield | 4.82% |
| FCF Yield | 5.88% |
Analyst Forecast
The average price target for Merck & Co. is $129.07, which is 29.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $129.07 |
| Price Target Difference | 29.46% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 3.75% |
| EPS Growth Forecast (5Y) | 105.78% |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.38 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.38 |
| Piotroski F-Score | 6 |